MaxCyte to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

MaxCyte, Inc. will participate in two upcoming investor conferences, including the Stifel 2023 Healthcare Conference Fireside Chat on November 15th and the Stephens Annual Investment Conference Fireside Chat on November 16th. The events will be webcasted live and archived on the MaxCyte investor relations website.

ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced Company management will participate at two upcoming investor conferences.

• Stifel 2023 Healthcare Conference
  Fireside Chat on Wednesday, November 15^th at 9:10am ET
  

• Stephens Annual Investment Conference
  Fireside Chat on Thursday, November 16^th at 9:00am CT
  

A live and archived webcast of the event will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.

MaxCyte Contacts:

US IR Adviser 
Gilmartin Group 
David Deuchler, CFA 
+1 415-937-5400 
ir@maxcyte.com  

US Media Relations 
Spectrum Seismic Collaborative 
Valerie Enes 
+1 408-497-8568 
valerie@spectrumscience.com

Nominated Adviser and Joint Corporate Broker 
Panmure Gordon 
Emma Earl / Freddy Crossley 
Corporate Broking 
Rupert Dearden 
+44 (0)20 7886 2500 

UK IR Adviser 
ICR Consilium Strategic Communications 
Mary-Jane Elliott 
Chris Welsh 
+44 (0)203 709 5700 
maxcyte@consilium-comms.com 

FAQ

What is the name of the company mentioned in the press release?

The company mentioned in the press release is MaxCyte, Inc.

What are the upcoming investor conferences that MaxCyte, Inc. will participate in?

MaxCyte, Inc. will participate in the Stifel 2023 Healthcare Conference Fireside Chat on November 15th and the Stephens Annual Investment Conference Fireside Chat on November 16th.

Where can I access the webcast of the events?

The webcast of the events will be available on the 'Events' section of the MaxCyte investor relations website at https://investors.maxcyte.com/.